Dynamic pharmacophore model optimization: Identification of novel HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1684-1692

  Deng, Jinxia ^a,b   Sanchez, Tino ^b   Neamati, Nouri ^b   Briggs, James M ^a  

^a University of Houston   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; MAGNESIUM ION; OXANTHRAZOLE;

ARTICLE; BINDING SITE; DRUG STRUCTURE; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MONTE CARLO METHOD; PHARMACOPHORE;

ALGORITHMS; ANTHRAQUINONES; BINDING SITES; CATIONS, DIVALENT; DATABASES, FACTUAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MAGNESIUM; MODELS, MOLECULAR; MONTE CARLO METHOD; PROTEIN BINDING; PYRAZOLES;

EID: 33644867878     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0510629     Document Type: Article

References (32)

1. Dayam, R.; Deng, J.; Neamati, N. HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev. 2006, in press.
2. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. Drug Discovery Today 1997, 2, 487-198.
3. Zhang, X.; Neamati, N.; Lee, Y. K.; Orr, A.; Brown, R. D.; Whitaker, N.; Pommier, Y.; Burke, T. R., Jr. Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase. Bioorg. Med. Chem. 2001, 9, 1649-1657.
4. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
5. Marchand, C.; Neamati, N.; Pommier, Y. In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol. 2001, 340, 624-633.
6. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: The 2001-2002 update. Curr. Pharm. Des. 2003, 9, 1789-1802.
7. Singh, S. B.; Zink, D. L.; Heimbach, B.; Genilloud, O.; Teran, A.; Silverman, K. C.; Lingham, R. B.; Felock, P.; Hazuda, D. J. Structure, stereochemistry, and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase. Org. Lett. 2002, 4, 1123-1126.
8. Young, S. L-780.810: A potent antiviral HIV integrase inhibitor with potential clinical utulity. The XIV International AIDS Conference, Barcelona, 2002.
9. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
10. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W.; Pommier, Y.; Burke, T. R., Jr. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
11. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R., Jr.; Pommier, Y.; Milne, G. W. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
12. Hong, H.; Neamati, N.; Winslow, H. E.; Christensen, J. L.; Orr, A.; Pommier, Y.; Milne, G. W. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chem. Chemother. 1998, 9, 461-472.
13. Carlson, H. A.; Masukawa, K. M.; Rubins, K.; Bushman, F. D.; Jorgensen, W. L.; Lins, R. D.; Briggs, J. M.; McCammon, J. A. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 2000, 43, 2100-2114.
14. Deng, J.; Lee, K. W.; Sanchez, T.; Cui, M.; Neamati, N.; Briggs, J. M. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J. Med. Chem. 2005, 48, 1496-1505.
15. Jorgensen, W. L. BOSS, 4.0 ed.; Yale University: New Haven, CT.
16. Jorgensen, W. L.; Tirado-Rives, J. The OPLS potential functions for proteins. Energy minimizations for crystal of cyclic peptides and crambin. J. Am. Chem. Soc. 1988, 110, 1657-1666.
17. Lee, M. C.; Deng, J.; Briggs, J. M.; Duan, Y. Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants. Biophys. J. 2005, 88, 3133-3146.
18. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
19. Cavasotto, C. N.; Abagyan, R. A. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 2004, 337, 209-225.
20. Barril, X.; Morley, S. D. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J. Med. Chem. 2005, 48, 4432-4443.
21. InsightII, 2000 ed.; Accelrys Inc.: San Diego.
22. Guex, N.; Peitsch, M. C. SWISS-MODEL and the Swiss-Pdb-Viewer: an environment for comparative protein modeling. Electrophoresis 1997, 18, 2714-2723.
23. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph 1996, 14, 33-38, 27-38.
24. Catalyst, 4.7 ed.; Accelrys Inc.: San Diego, CA.
25. Jenkins, T. M.; Esposito, D.; Engelman, A.; Craigie, R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photocrosslinking. EMBO J. 1997, 16, 6849-6859.
26. Drake, R. R.; Neamati, N.; Hong, H.; Pilon, A. A.; Sunthankar, P.; Hume, S. D.; Milne, G. W.; Pommier, Y. Identification of a nucleotide binding site in HIV-1 integrase. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4170-4175.
27. Lins, R. D.; Adesokan, A.; Soares, T. A.; Briggs, J. M. Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol. Ther. 2000, 85, 123-131.
28. Shannon, R. D. Revised effective ionic radii and systematic studies of interatomic distances in Halides and Chalcogenides. Acta Crystallogr. 1976, A32, 751-767.
29. Christmann-Franck, S.; Bertrand, H. O.; Goupii-Lamy, A.; der Garabedian, P. A.; Mauffret, O.; Hoffmann, R.; Fermandjian, S. Structure-based virtual screening: An application to human topoisomerase II alpha. J. Med. Chem. 2004. 47, 6840-6853.
30. Singh, S. B.; Jayasuriya, H.; Dewey, R.; Polishook, J. D.; Dombrowski, A. W.; Zink, D. L.; Guan, Z.; Collado, J.; Platas, G.; Pelaez, F.; Felock, P. J.; Hazuda, D. J. Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. J. Ind. Microbiol. Biotechnol. 2003, 30, 721-731.
31. Fesen, M. R.; Kohn, K. W.; Leteurtre, F.; Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2399-2403.
32. Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez, R. P.; Wai, J. S.; Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R. M.; Witmer, M. V.; Wilson, K. A.; Tussey, L.; Schleif, W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.; Casimiro, D. R.; Emini, E. A.; Shiver, J. W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.